Gill David N is a director of Y-Mabs Therapeutics Inc.
Person profile
Latest filings (excl ownership)
No filings
Latest ownership filings
4
Evolus, Inc.
9 Feb 24
4
Y-mAbs Therapeutics, Inc.
9 Jun 23
4
Evolus, Inc.
31 Jan 23
4
Y-mAbs Therapeutics, Inc.
19 Jul 22
4
Evolus, Inc.
17 May 22
4
Evolus, Inc.
26 Jan 22
4
Strongbridge Biopharma plc
6 Oct 21
4
Strongbridge Biopharma plc
5 Oct 21
4
Y-mAbs Therapeutics, Inc.
14 Jun 21
4
Strongbridge Biopharma plc
18 May 21
Recent insider trades
Date | Company | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
7 Feb 24 | EOLS Evolus | Common Stock | Grant | Acquire A | No | No | 0 | 6,464 | 0.00 | 44,325 |
7 Feb 24 | EOLS Evolus | Stock Option Common Stock | Grant | Acquire A | No | No | 13.15 | 9,377 | 123.31 k | 9,377 |
8 Jun 23 | YMAB Y-Mabs Therapeutics | Common Stock | Grant | Acquire A | No | No | 0 | 2,330 | 0.00 | 2,330 |
8 Jun 23 | YMAB Y-Mabs Therapeutics | Employee Stock Option Common stock | Grant | Acquire A | No | No | 8.13 | 13,950 | 113.41 k | 13,950 |
27 Jan 23 | EOLS Evolus | Common Stock | Grant | Acquire A | No | No | 0 | 8,293 | 0.00 | 37,861 |
27 Jan 23 | EOLS Evolus | Stock Option Common Stock | Grant | Acquire A | No | No | 10.25 | 11,789 | 120.84 k | 11,789 |